A Malaysian doctor is leading a clinical drug trial in Chicago, United States, that has been found to double one year survival of pancreatic cancer patients, offering new hope against one of the deadliest forms of cancer.

Dr Devalingam Mahalingam, who is heading the study at Northwestern University, said the treatment significantly improved outcomes among patients with advanced pancreatic cancer, a disease in which most sufferers survive less than a year after diagnosis. The phase 2 randomized trial shows 38% reduction in risk of death with the drug when combined with chemotherapy.

“Pancreatic cancer remains one of the most challenging solid tumors to treat, but these findings provide cautious optimism for patients,” said study lead author Dr. Devalingam Mahalingam, professor of medicine in the division of Hematology and Oncology at Northwestern University Feinberg School of Medicine, in the news release by the university.

“While these results will need to be confirmed in phase 3 trials, observing survival benefit in such a difficult-to-treat cancer is encouraging. Given the novel mechanism of this drug, these findings raise the possibility that it could have broader application across other tumor types,” added Mahalingam, who also is the associate director of clinical research at Robert H. Lurie Comprehensive Cancer Center of Northwestern University

The new randomised phase 2 trial published in the Nature Medicine suggests that adding the experimental drug elraglusib to standard chemotherapy may improve survival for people with metastatic pancreatic cancer, a disease with a typically poor prognosis (outcome).

“Phase 2 randomized trial shows 38% reduction in risk of death with the drug when combined with chemotherapy”

The finding offers cautious hope for patients and families confronting one of the deadliest common cancers, while underscoring the need for larger confirmatory trials.

Pancreatic cancer is notoriously hard to treat.

Many people are diagnosed at an advanced stage and median survival for metastatic disease is commonly measured in months rather than years. Standard first‑line chemotherapy regimens aim to slow tumour growth and relieve symptoms, but improvements in overall survival over the past decade have been limited.

Elraglusib is an experimental small‑molecule drug developed at Northwestern University that targets an enzyme called glycogen synthase kinase‑3 beta, usually shortened to GSK‑3β. This enzyme is involved in a range of cellular processes, including cell proliferation and immune signalling.

Targeting GSK‑3β is a different approach from conventional chemotherapy, and the drug is being explored because it may alter the tumour microenvironment and immune response rather than directly kill cancer cells.

What the new research shows

The trial was a randomised, international phase 2 study that enrolled 233 patients with metastatic pancreatic cancer at 60 sites in North America and Europe. Participants were assigned to receive standard chemotherapy with or without elraglusib.

Key findings from the published report are:

• Median overall survival was 10.1 months in the elraglusib plus chemotherapy arm and 7.2 months in the chemotherapy‑only arm.
• The analysis reported a 38% reduction in the risk of death for patients receiving elraglusib plus chemotherapy compared with chemotherapy alone.
• The proportion alive at one year was 44% in the elraglusib group versus 22% in the chemotherapy group.
• About 13% of patients in the elraglusib arm were alive at two years, compared with none in the control arm.
• Side effects were generally those expected with chemotherapy (for example, low white blood cell counts and fatigue) but occurred slightly more often in the elraglusib group; temporary vision changes were also reported and were reversible.

These results come from a human clinical trial and represent an improvement in survival measures compared with chemotherapy alone in this study population.

How elraglusib may work

Elraglusib inhibits GSK‑3β, a kinase that influences multiple cellular pathways. In the context of cancer, GSK‑3β can support tumour cell survival and contribute to the immune‑suppressive characteristics of the tumour microenvironment — the mix of cancer cells, immune cells and supporting tissue around a tumour.

The trial team reports that patients treated with elraglusib showed increases in immune cells associated with anti‑tumour activity within their tumours.

In plain terms, the drug appears to shift the local immune environment so that immune cells that can attack cancer are more present or active.

The researchers also found that certain immune markers in the blood before treatment were linked with longer survival among patients given elraglusib, suggesting some people’s immune systems may be more likely to respond.

How strong the evidence is

The results are encouraging but preliminary. Strengths of the study include randomisation, a reasonably sized patient group for phase 2, and an international, multi‑centre design.

However, several important limitations should be noted:

• Phase 2 trials are designed to evaluate safety and signals of efficacy; they are not definitive proof that a drug prolongs life for all patients.
• The trial included patients whose disease progressed rapidly and could not benefit from treatment, which affects median survival comparisons.
• The reported reduction in risk of death and improvements in one‑ and two‑year survival require confirmation in a larger phase 3 trial to exclude chance findings and to better define which patients benefit most.

What this means for patients and the public

For people with metastatic pancreatic cancer, these findings are a cautiously encouraging sign that new approaches may modestly extend survival for some patients.

Importantly, this result does not immediately change standard clinical practice. Elraglusib is still experimental and not widely available outside of clinical trials.

Patients should not alter their treatment decisions based on this single phase 2 trial. Those interested in experimental therapies should discuss trial eligibility with their oncology team and consider participation in clinical studies conducted at experienced centres. Always consult your healthcare providers for medical advice.

Treatments, prevention and policy implications

Current standard treatments for metastatic pancreatic cancer include combination chemotherapy regimens such as FOLFIRINOX or gemcitabine plus nab‑paclitaxel, chosen based on patient fitness and tumours’ characteristics.

The addition of elraglusib to chemotherapy would represent a new combination strategy that aims to augment anti‑tumour immunity while chemotherapy controls tumour burden.

If larger trials confirm benefit and safety, elraglusib could become an additional option for patients. Policymakers and funders may need to consider supporting phase 3 testing and, if positive, pathways for regulatory review and reimbursement.

Any future approval would also require careful assessment of which patient subgroups gain the most benefit and how to manage additional side effects.

What remains unknown and what comes next

Key unanswered questions include:

• Can the survival benefit be reproduced in a larger phase 3 trial?
• Which patients are most likely to benefit? Early biomarker data hint that baseline immune markers may predict response, but this requires validation.
• How should elraglusib be combined with other therapies, such as immunotherapies or targeted agents?
• What is the long‑term safety profile beyond what was observed in the phase 2 trial?

The authors report plans to explore a phase 3 confirmatory trial as funding and partnerships allow, and to test elraglusib with other novel therapies.

Cautious Optimism

This phase 2 trial suggests elraglusib, when added to standard chemotherapy, may extend survival for some people with metastatic pancreatic cancer and appears to act in part by altering the tumour immune environment.

The findings are promising but not definitive.

Larger, independent trials are needed to confirm benefit, to identify which patients will gain the most, and to establish how best to integrate the drug into care.

For now, the study provides a reason for cautious optimism and a clear direction for further research rather than a change in treatment practice.